Leishmania braziliensis enhances monocyte responses to promote anti-tumor activity
Cell Reports, 2024
dos Santos J., Moreno M., Teufel L., Chilibroste S., Keating S., Groh L., Domínguez-Andrés J., Williams D., Ma Z., Lowman D., Ensley H., Novakovic B., Ribeiro-Dias F., Netea M., Chabalgoity J., Joosten L.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology Immunotherapy | Pathophysiology | Serum |  Olink Target 96 Mouse |
Abstract
Innate immune cells can undergo long-term functional reprogramming after certain infections, a process called trained immunity (TI). Here, we focus on antigens of Leishmania braziliensis, which induced anti-tumor effects via trained immunity in human monocytes. We reveal that monocytes exposed to promastigote antigens of L. braziliensis develop an enhanced response to subsequent exposure to Toll-like receptor (TLR)2 or TLR4 ligands. Mechanistically, the induction of TI in monocytes by L. braziliensis is mediated by multiple pattern recognition receptors, changes in metabolism, and increased deposition of H3K4me3 at the promoter regions of immune genes. The administration of L. braziliensis exerts potent anti-tumor capabilities by delaying tumor growth and prolonging survival of mice with non-Hodgkin lymphoma. Our work reveals mechanisms of TI induced by L. braziliensis in vitro and identifies its potential for cancer immunotherapy.